Flag­ship, Arch cut their loss­es, qui­et­ly shut­ter En­sem­ble Ther­a­peu­tics as pipeline plans fiz­zle out

Here’s an­oth­er cau­tion­ary tale to keep in mind dur­ing the go-go years of the US biotech scene.

Af­ter get­ting start­ed with more than $40 mil­lion in re­port­ed eq­ui­ty in­vest­ments from a broad group of A-list in­vestors like Flag­ship and Arch, En­sem­ble Ther­a­peu­tics went on to ink a long line­up of dis­cov­ery deals with some promi­nent play­ers like No­var­tis, Pfiz­er and Bris­tol-My­ers.

But it wasn’t enough.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER